Although atezolizumab, an anti PD-L1 antibody, combined with nab-paclitaxel was recently approved for patients with TNBC by the US Food and Drug Administration after the IMpassion130 trial [100,101]; the overall response rate to immune checkpoint inhibitors in advanced breast cancer is generally low, around 15%, as demonstrated for other cancer types [102]. Here, CD274 is linked to cancer.